BioXcel Therapeutics, Inc. — Director's Dealing 2019

Aug 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2019-08-16

Reporting Person: Mehta Vimal (Director, CEO, President and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-16	Common Stock	P	974	$8.89	Acquired	9957	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.73 to $9.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.